Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | EU-OPENSCREEN | Collaborative Drug Discovery, Inc. |
Test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chemical registration system Activity & Registration - Web application within CDD Vault for chemical registration, assay data management, and SAR analysis. |
Partnerships |
Events |
Jobs |
Sanofi and Joslin Diabetes Center to Develop New Drugs for Diabetic CareJoslin Diabetes Center a teaching and research affiliate of Harvard Medical School and Sanofi have entered into a partnership agreement to develop new drugs to treat diabetes. Under this collaboration, Sanofi will have the right to commercialize... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Senex BiotechnologyThe mission of Senex Biotechnology is to discover and develop therapeutic agents to effectively treat cancer, viral diseases and age-related diseases, such as Alzheimer's, renal disease, atherosclerosis, and arthritis, by targeting damage-inducible... View all |
No EVENTS for listing |
No Job Posts |
